Literature DB >> 12720122

The malignant clone in Waldenstrom's macroglobulinemia.

Jitra Kriangkum1, Brian J Taylor, Michael J Mant, Steven P Treon, Andrew R Belch, Linda M Pilarski.   

Abstract

The unique IgM VDJ sequence that characterizes the malignant clone in Waldenstrom's macroglobulinemia (WM), termed clonotypic, was identified for 12 WM patients. The majority of WM patients (92%) had a clonotypic IgM from the VH3 family, with predominantly long CDR3 regions, characteristic of those found in antigen-stimulated populations. Clonotypic IgM transcripts were detected in both blood and bone marrow (BM), clearly identifying a blood-borne compartment of WM. Abnormal numbers of CD20(+) B cells were usually detectable and expressed surface IgM. In most cases these cells also expressed surface IgD. Most WM patients lacked detectable CD138(+) plasma cells in either blood or BM. Longitudinal analysis suggests that phenotypic identification of B cells in blood of WM patients is insufficient for monitoring disease. Although serum IgM had decreased and clonotypic transcripts were very weak for one patient, the number of CD20(+) B cells increased dramatically. The lack of clonotypic transcripts suggests that the majority of these circulating B cells were polyclonal and were not part of the WM clone, indicating that monitoring of clonotypic IgM provides the most accurate identifier of WM cells. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720122     DOI: 10.1053/sonc.2003.50061

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.

Authors:  Loizos Petrikkos; Marie-Christine Kyrtsonis; Maria Roumelioti; George Georgiou; Anna Efthymiou; Tatiana Tzenou; Panayiotis Panayiotidis
Journal:  Biomed Res Int       Date:  2014-08-14       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.